ArticleFrontiers in molecular neuroscience2026
Beyond development: LINX/Islr2 expression and TrkA interaction in the adult nervous system under neuroinflammatory challenge.
Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: LINX, also known as immunoglobulin superfamily containing leucine-rich repeat 2 (Islr2), was identified as a TrkA pathway component and demonstrated to modulate the NGF/TrkA-mediated axonal growth, guidance, and branching during development. However, there is limited information on LINX expression in the adult nervous system, and the possible functions of LINX in mature neurons remain unexplored. These two questions are addressed by the present study, which first investigates LINX expression in the adult spinal cord (SC), dorsal root ganglia (DRG), and cerebral cortex (Cx), and subsequently explores LINX/TrkA functions using the DRG organ culture model. Methods: Different commercially available anti-LINX antibodies were tested, and the most selective antibody was used to investigate LINX expression in the SC, Cx, and DRG of healthy rats, and to explore the LINX/TrkA action in DRG organ cultures using a model of neuroinflammation/injury induced by lipopolysaccharides (LPS). The LINX/TrkA interaction was demonstrated by immunoprecipitation in the Cx of healthy and LPS-treated rats. The DRG from healthy and LPS-treated rats were dissected and cultured in the presence of anti-LINX, with or without stimulation using NGF, and a TrkA selective inhibitor. TrkA phosphorylation levels and the expression of the axonal growth marker GAP43 were analyzed by bio-molecular assays and confocal immunofluorescence microscopy. Results: The WB analysis shows that LINX is expressed in the adult central and peripheral nervous systems, and the immunoprecipitation analysis demonstrates LINX and TrkA interaction in the Cx of both adult healthy and LPS-treated rats. Discussion: Our study confirms that LINX is expressed in the adult central nervous system and demonstrates that the LINX/TrkA interaction is maintained following LPS-induced systemic inflammation. Moreover, our findings that antibody-mediated perturbation of endogenous LINX is associated with the modulation of axonal growth markers in adult LP-DRG cultures, in serum-free conditions and/or in the presence of a TrkA inhibitor, suggest a potential role for LINX in regulating neurotrophin-dependent responses in injured adult neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.